| Rating | Rating / ranking1 | Status |
|---|---|---|
| Access to Medicine Index (ATMI) | 1st | Among top 4 since 2014 |
| MSCI | AAA | ESG Leaders group |
| ISS ESG | B | ESG Leaders group, Prime status |
| Sustainalytics* | Low Risk | ESG Leaders group |
| CDP Climate Change | A | Double A List status (since 2022) |
| CDP Water Security | A |
Last update: August 2025
1. Rating/ranking scales: ATMI: Out of the 20 largest research-based pharmaceutical companies as selected by the Access to Medicine Foundation; MSCI: CCC to AAA; ISS ESG: D- to A+; Sustainalytics: Negligible to Severe risk; CDP: D- to A
* Copyright © 2025 Sustainalytics, a Morningstar company. All rights reserved. This publication includes information and data provided by Sustainalytics and/or its content providers. Information provided by Sustainalytics is not directed to or intended for use or distribution to India-based clients or users and its distribution to Indian resident individuals or entities is not permitted. Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect. Use of such data is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.